Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 5/20 | 0.36 |
| ▸ | MMP2 | P08253 | 4/20 | 0.36 |
| ▸ | MMP9 | P14780 | 4/20 | 0.36 |
| ▸ | ACE | P12821 | 1/20 | 0.34 |
| ▸ | ADAM17 | P78536 | 3/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7528125 | 1.00 | MMP1 (0.36) | MMP1MMP2MMP9ACEADAM17 | |
| SCHEMBL7528129 | 1.00 | MMP1 (0.36) | MMP1MMP2MMP9ACEADAM17 | |
| SCHEMBL3533072 | 0.87 | MMP1 (0.33) | MMP1MMP2MMP9ADAM17KMT2A | |
| Hydrochloric Acid SCHEMBL3530197 | 0.83 | MMP1 (0.36) | MMP1MMP2MMP9ADAM17 | |
| SCHEMBL18806165 | 0.83 | — | — | |
| SCHEMBL1527328 | 0.82 | SMN1; SMN2 (0.34) | MMP1MMP2MMP9ACEADAM17 | |
| SCHEMBL1527326 | 0.82 | SMN1; SMN2 (0.34) | MMP1MMP2MMP9ACEADAM17 | |
| SCHEMBL13751286 | 0.79 | DPP4 (0.38) | — | |
| SCHEMBL13740583 | 0.79 | DPP4 (0.38) | — | |
| SCHEMBL9733830 | 0.79 | SMN1; SMN2 (0.34) | MMP1MMP2MMP9ACEADAM17 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020187934-A1 | Peptide derivatives | SYNGENTA LIMITED (GB) | 2002-12-12 | — | — | US | disclosed |
| US-20020103335-A1 | PEPTIDE DERIVATIVES | ASTRAZENECA UK LIMITED (GB) | 2002-08-01 | — | — | US | disclosed |
| US-6087336-A | ANTIINFLAMMATORY AGENT TREATING RHEUMATOID ARTHRITIS | ZENECA LIMITED (GB) | 2000-07-11 | — | — | US | disclosed |
| EP-0946596-A1 | PEPTIDE DERIVATIVES | ZENECA LIMITED (GB) | 1999-10-06 | — | — | EP | disclosed |
| EP-0914333-A1 | PEPTIDE DERIVATIVES | ZENECA LIMITED (GB) | 1999-05-12 | — | — | EP | disclosed |
| EP-0882066-A1 | PEPTIDE DERIVATIVES | ZENECA LIMITED (GB) | 1998-12-09 | — | — | EP | disclosed |
| WO-1998023644-A1 | PEPTIDE DERIVATIVES | ZENECA LIMITED (GB) | 1998-06-04 | — | — | WO | disclosed |
| WO-1997046578-A1 | PEPTIDE DERIVATIVES | ZENECA LIMITED (GB) | 1997-12-11 | — | — | WO | disclosed |
| WO-1997031023-A1 | PEPTIDE DERIVATIVES | ZENECA LIMITED (GB) | 1997-08-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020103335-A1 | PEPTIDE DERIVATIVES | HLA-DRB1, MICA, TAP1 | MMP1 2211/4885MMP2 2556/4885MMP9 3133/4885 |
| US-20020187934-A1 | Peptide derivatives | HLA-DRB1, MICA, TAP1 | MMP1 980/4885MMP2 2180/4885MMP9 2603/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.